Sutro Biopharma
STRO
59 hedge funds and large institutions have $101M invested in Sutro Biopharma in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 24 increasing their positions, 14 reducing their positions, and 5 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 14
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
2% more funds holding
Funds holding: 58 → 59 (+1)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.32% less ownership
Funds ownership: 5.15% → 4.83% (-0.32%)
25% less capital invested
Capital invested by funds: $134M → $101M (-$33.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$3.48M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.29M |
| 3 |
BlackRock
New York
|
+$1.01M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$420K |
| 5 |
Morgan Stanley
New York
|
+$234K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$7.27M |
| 2 |
SCM
Sio Capital Management
New York
|
-$3.86M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.67M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$555K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$235K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
BNP Paribas Financial Markets
Paris,
France
| $11.6K | +$909 | +9 | +8% |
|
52
Citigroup
New York
| $9K | -$18.6K | -184 | -65% |
|
53
Bank of Montreal
Toronto,
Ontario, Canada
| $9K | +$303 | +3 | +3% |
|
|
PAM
54
Panagora Asset Management
Boston,
Massachusetts
| $6K | -$1.31K | -13 | -16% |
|
|
APA
55
American Portfolios Advisors
Holbrook,
New York
| $5.45K | +$6.06K | +60 | New |
|
|
AIP
56
Ameritas Investment Partners
Lincoln,
Nebraska
| $5K | – | – | – |
|
|
MAM
57
Meeder Asset Management
Dublin,
Ohio
| $3K | +$2.93K | +29 | New |
|
|
AG
58
Advisor Group
Phoenix,
Arizona
| $2K | – | – | – |
|
|
TRCT
59
Tower Research Capital (TRC)
New York
| $1K | -$11K | -109 | -91% |
|
|
SCM
60
Sio Capital Management
New York
| – | -$3.86M | -33,906 | Closed |
|
|
61
Point72 Asset Management
Stamford,
Connecticut
| – | -$3.67M | -32,238 | Closed |
|
|
SIM
62
Spark Investment Management
New York
| – | -$160K | -1,410 | Closed |
|
|
FIA
63
FNY Investment Advisers
New York
| – | -$16K | -147 | Closed |
|
|
CSS
64
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$11K | -96 | Closed |
|
STRO Hedge Fund Activity: Q3 2019 in Review
59 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q3 2019, worth a combined $101M — down 25% from $134M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new STRO positions and 5 closed out — a net gain of 1 holder — while 24 added to existing stakes and 14 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $3.48M. The largest seller was Eventide Asset Management, cutting an estimated $7.27M.
- 59 institutional investors held Sutro Biopharma (STRO) as of Q3 2019, up from 58 in Q2 2019.
- Funds reported $101M of Sutro Biopharma stock for Q3 2019, down 25% quarter-over-quarter.
- 6 funds opened new Sutro Biopharma positions in Q3 2019 and 5 closed out, a net change of +1 holder.
- The largest Sutro Biopharma buyer in Q3 2019 was BVF Inc, an estimated $3.48M added.
- The largest Sutro Biopharma seller in Q3 2019 was Eventide Asset Management, an estimated $7.27M sold.
Based on aggregated 13F filings for Q3 2019.